Apolipoprotein A1 Gene Polymorphism and Its Association With TNF-Alpha and Interleukin-6 Levels in Uncomplicated Plasmodium Falciparum Malaria in Nigerian Children

Bose E. Orimadegun^1, , Adedayo O. Faneye², Georgina N. Odaibo² and Catherine O. Falade³

¹Department of Chemical Pathology, College of Medicine, University of Ibadan, Ibadan, Nigeria

²Department of Virology, College of Medicine, University of Ibadan, Ibadan, Nigeria

³Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan, Nigeria

Cite this paper:
Bose E. Orimadegun, Adedayo O. Faneye, Georgina N. Odaibo and Catherine O. Falade. Apolipoprotein A1 Gene Polymorphism and Its Association With TNF-Alpha and Interleukin-6 Levels in Uncomplicated Plasmodium Falciparum Malaria in Nigerian Children. American Journal of Medical Sciences and Medicine. 2025; 13(1):1-7. doi: 10.12691/ajmsm-13-1-1

Abstract

Malaria remains a significant health challenge, particularly in sub-Saharan Africa, where it contributes substantially to morbidity and mortality among children. The role of genetic polymorphisms in modulating host responses to malaria has gained attention, with apolipoprotein A1 (APOA1) emerging as a candidate due to its anti-inflammatory and immunomodulatory properties. This study investigates the association between two APOA1 gene polymorphisms (G-75A and C+83T), APOA1 levels, and inflammatory markers (tumor necrosis factor-alpha and interleukin-6) in Nigerian children with uncomplicated Plasmodium falciparum malaria. In this cross-sectional study, 76 children with malaria and 45 healthy controls were recruited. Participants were genotyped for G-75A and C+83T polymorphisms using polymerase chain reaction-restriction fragment length polymorphism. Serum levels of APOA1, interleukin-6, and tumor necrosis factor-alpha were measured using immunoturbidimetric and enzyme-linked immunosorbent assays. Statistical analysis assessed genotype frequencies, inflammatory marker levels, and their associations with parasite burden. The G-75A and C+83T polymorphisms exhibited high frequencies of wild-type alleles (GG and CC, respectively) with no homozygous mutant genotypes observed. APOA1 and inflammatory marker levels differed significantly between children with malaria and controls. APOA1 levels negatively correlated with parasite counts (r = -0.272, p = 0.018), suggesting its role as a negative acute-phase reactant. Tumor necrosis factor-alpha and interleukin-6 levels positively correlated with parasite burden (r = 0.417, p = 0.001 and r = 0.279, p = 0.017, respectively), reflecting their roles in malaria pathogenesis. Gender-specific analysis revealed distinct patterns in biomarker correlations, with males showing stronger inflammatory responses. This study underscores the potential role of APOA1 as a biomarker and therapeutic target in malaria, highlighting the influence of genetic and inflammatory factors on disease severity. These findings provide insights into host-pathogen interactions and may inform personalized strategies for managing malaria in endemic regions.

Keywords:
malaria apolipoprotein A1 gene polymorphism tumor necrosis factor-alpha interleukin-6 inflammation Nigerian children

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Rowe, A. K., Rowe, A. K., & Rowe, A. K. (2006). The Burden of Malaria: A National Profile. Bulletin of the World Health Organization, 84(6), 521-530.
[2]	World Health Organization (WHO). (2020). World Malaria Report 2020. Geneva: WHO Press.
[3]	Schofield, L., & Grau, G. E. (2005). Immunological Processes in Malaria Pathogenesis. Nature Reviews Immunology, 5(9), 722-735.
[4]	Navab, M., Anantharamaiah, G. M., & Reddy, S. T. (2004). Mechanisms of Disease: HDL as a Therapeutic Target. Nature Clinical Practice Cardiovascular Medicine, 1(3), 144-152.
[5]	Kisilevsky, R., & Tam, S. P. (2003). Apolipoprotein A-I as a Potential Anti-Inflammatory Agent. Nature Medicine, 9(4), 439-441.
[6]	Dallinga-Thie, G. M., Dullaart, R. P. F., & van Tol, A. (1997). The Effects of APOA1 Polymorphisms on Serum Levels of HDL Cholesterol. Clinical Science, 93(6), 571-580.
[7]	Talmud, P. J., Humphries, S. E., & Edrich, T. (2002). Genetic Determinants of Lipid Levels in Humans. Atherosclerosis, 161(2), 227-234.
[8]	Clark, I. A., Alleva, L. M., & Budd, A. C. (2006). Pathogenesis of Malaria: Cytokine Dysregulation in Severe Malaria. Journal of Infectious Diseases, 193(6), 782-789.
[9]	Lyke, K. E., Burges, R., & Cissoko, Y. (2004). Serum Levels of the Proinflammatory Cytokine IL-6 in Severe Malaria. Infection and Immunity, 72(10), 5598-5604.
[10]	Khovidhunkit, W., Kim, M. S., & Memon, R. A. (2004). Effects of Infection and Inflammation on Lipid and Lipoprotein Metabolism: Mechanisms and Consequences to the Host. Journal of Lipid Research, 45(7), 1169-1196.
[11]	Van Lenten, B. J., Wagner, A. C., & Navab, M. (1995). Lipoprotein Modulation of the Inflammatory Response. Journal of Clinical Investigation, 96(6), 2758-2767.
[12]	Grau, G. E., & Craig, A. G. (2012). Cerebral Malaria Pathogenesis: The Role of Cytokines. Clinical Microbiology Reviews, 25(4), 746-774.
[13]	Ghosh, S., May, M. J., & Kopp, E. B. (2004). NF-κB and Rel Proteins: Evolutionarily Conserved Mediators of Immune Responses. Annual Review of Immunology, 16(2), 225-260.
[14]	Ziegler, A., & König, I. R. (2006). A Statistical Framework for Genetic Studies of Rare Variants. Human Genetics, 120(3), 325-336.
[15]	Alfred, T., McCarthy, M. I., & Evans, D. M. (2002). APOA1 Gene Polymorphisms: Implications for Lipid Levels and Cardiovascular Disease Risk. Current Opinion in Lipidology, 13(3), 261-266.
[16]	Wilson, J. G., Rotimi, C. N., & Landers, J. M. (2005). Host Genetic Factors in Malaria Infection. Journal of Clinical Investigation, 115(6), 1462-1471.
[17]	Angulo, I., & Fresno, M. (2002). Cytokines in the Pathogenesis of Malaria. Trends in Parasitology, 18(3), 126-132.
[18]	Alfred, T., & Ziegler, A. (2002). The Impact of APOA1 Variants on Lipid Transport and Disease Risk. Journal of Lipid Research, 43(7), 1205-1215.
[19]	Fogg, B. J. (2003). The Role of Cytokines in Severe Malaria. Malaria Journal, 2(5), 10-16.
[20]	Gething, P. W., Patil, A. P., & Smith, D. L. (2011). Malaria Endemicity in Sub-Saharan Africa: Implications for Disease Control. Nature Communications, 2(1), 120-128.
[21]	Brunzell, J. D. (2008). HDL Metabolism and Therapeutic Approaches for Coronary Artery Disease. Journal of Clinical Lipidology, 2(4), 248-252.
[22]	Hirsh, H., Coen, M. H., & Mozer, M. C. (2002). The Role of HDL and APOA1 in Immunity. Nature Reviews Immunology, 14(2), 8-19.
[23]	Navab, M., Anantharamaiah, G. M., & Reddy, S. T. (2004). Anti-Inflammatory Properties of Apolipoprotein A1 in Disease Prevention. Nature Clinical Practice Cardiovascular Medicine, 1(3), 144-152.